http://localhost:8080/xmlui/handle/123456789/4372 435-522 (Desember, 2020) 2026-04-08T21:37:28Z http://localhost:8080/xmlui/handle/123456789/4391 Title: Health services in northern Australia depend on student placements post COVID-19 Authors: Campbell, Narelle; Stothers, Kylie; Swain, Lindy; Cairns, Alice; Dunsford, Ella; Rissel, Chris; Barker, Ruth 2020-12-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/4390 Title: Affording health during the COVID-19 pandemic and associated economic downturn Authors: Lewis, Meron; Lee, Amanda J. 2020-12-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/4389 Title: Dementia case ascertainment using aged care assessment data Authors: Cations, Monica; Lang, Catherine; Ward, Stephanie A.; Crotty, Maria; Inacio, Maria C. 2020-12-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/4388 Title: Prevalence of Hepatitis C and treatment uptake in regional Victoria Authors: Glenister, Kristen; Kemp, William; Tomic, Dunya; Simmons, David; Roberts, Stuart Abstract: Objective: The objective of this study was to assess the prevalence of hepatitis C virus (HCV) in regional Victoria and assess amenability to treatment. Methods: Households were randomly selected and one adult from each was invited to a ‘clinic’, which included HCV, liver function and liver stiffness/fibrosis tests. Participants reactive to HCV were asked about their amenability to treatment. Results: The study identified eight cases of HCV (antibody and PCR reactive, 1.1%) among 748 participants, half of which were new diagnoses. Most of the HCV-reactive participants were male (89%). Liver function and fibrosis were not significantly different between HCV-reactive and non-reactive participants. Most participants notified of their HCV were amenable to treatment. Conclusions: The prevalence of HCV in this regional Victorian study (1.1%) was similar to the Australian modelled prevalence estimates. Most participants were amenable to treatment. Implications for public health: The unique opportunity to eliminate HCV requires a reorientation of the public health response toward systematic implementation of treatment to address barriers and reduce stigma and discrimination for marginalised populations. This should include targeting regional areas where the HCV prevalence of undiagnosed cases may be higher than metropolitan areas. 2020-12-01T00:00:00Z